<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902026000101203</article-id>
<article-id pub-id-type="doi">10.29193/rmu.42.1.4</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Adherencia a la indicación de tromboprofilaxis farmacológica en pacientes hospitalizados: experiencia con 2 modelos de evaluación de riesgo en pacientes con patología médica en dos centros terciarios en Uruguay]]></article-title>
<article-title xml:lang="en"><![CDATA[Adherence to the indication of pharmacological thromboprophylaxis in hospitalized patients: experience with two risk-assessment models in patients with medical conditions in two tertiary centers in Uruguay]]></article-title>
<article-title xml:lang="pt"><![CDATA[Adesão à indicação de tromboprofilaxia farmacológica em pacientes hospitalizados: experiência com dois modelos de avaliação de risco em pacientes com condições médicas em dois centros terciários no Uruguai]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Millar]]></surname>
<given-names><![CDATA[Romina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Da Silveira]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mérola]]></surname>
<given-names><![CDATA[Valentina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pizzarossa]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Facultad de Medicina Unidad Académica Clínica Médica C, Hospital de Clínicas]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Corporación Médica de Canelones  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2026</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2026</year>
</pub-date>
<volume>42</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902026000101203&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902026000101203&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902026000101203&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: la enfermedad tromboembólica venosa (ETV) es una complicación médica grave, frecuente y prevenible en el paciente hospitalizado. Si bien se ha demostrado la eficacia de su prevención, la adherencia a la tromboprofilaxis es insuficiente a nivel internacional y nacional.  Objetivos: analizar el riesgo de ETV y el cumplimiento de la indicación de tromboprofilaxis farmacológica en pacientes hospitalizados.  Metodología: estudio observacional, descriptivo, prospectivo de pacientes no críticos con patología médica, quirúrgica o en período gravido-puerperal en dos centros médicos terciarios del Uruguay. Se estudió el porcentaje de pacientes en riesgo de ETV y, dentro de ellos, se valoró el porcentaje que recibía tromboprofilaxis farmacológica. A los 3 meses, se valoró si tuvieron un evento de ETV.  Resultados: se incluyeron 229 pacientes. Del total de pacientes, el 68,1% se encontraban en riesgo de ETV usando score PADUA, de los cuales el 53,2% recibían profilaxis farmacológica. Si se utiliza el score UTAH, el 72,5% se encontraban en riesgo de ETV, de los cuales el 53% recibía profilaxis farmacológica. Ninguno de los pacientes con contraindicación para tromboprofilaxis farmacológica recibió medidas mecánicas. El 26,2% de los pacientes con patología quirúrgica en riesgo de ETV recibía tromboprofilaxis farmacológica. Diez pacientes con patología médica estaban en riesgo según el score UTAH, pero no el PADUA. Se logró el seguimiento de 148 pacientes a los 3 meses, 2 (1,4%) presentaron un evento trombótico. Ambos tenían contraindicación para tromboprofilaxis farmacológica.  Conclusiones: la adherencia a la prescripción de tromboprofilaxis es aún insuficiente y se debe seguir trabajando.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: venous thromboembolism (VTE) is a serious, frequent, and preventable medical complication in hospitalized patients. Although the efficacy of its prevention has been demonstrated, adherence to thromboprophylaxis remains insufficient at both international and national levels.  Objectives: to analyze VTE risk and adherence to pharmacological thromboprophylaxis among hospitalized patients.  Methods: observational, descriptive, prospective study including non-critical patients with medical, surgical, or gravidpuerperal conditions in two tertiary medical centers in Uruguay. The percentage of patients at risk of VTE was assessed, and among them, the proportion receiving pharmacological thromboprophylaxis was evaluated. At 3 months, the occurrence of a VTE event was determined.  Results: a total of 229 patients were included. Of all patients, 68.1% were at risk of VTE according to the PADUA score, of whom 53.2% were receiving pharmacological prophylaxis. When the UTAH score was applied, 72.5% were at risk of VTE, of whom 53% were receiving pharmacological prophylaxis. None of the patients with a contraindication to pharmacological thromboprophylaxis received mechanical measures. 26.2% of patients with surgical pathology at risk of VTE were receiving pharmacological thromboprophylaxis. Ten patients with medical pathology were at risk according to the UTAH score but not according to PADUA. Follow-up at 3 months was achieved in 148 patients; 2 (1.4%) experienced a thrombotic event. Both had contraindications to pharmacological thromboprophylaxis.  Conclusions: adherence to thromboprophylaxis prescription remains insufficient and continued efforts are needed.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução: a doença tromboembólica venosa (TEV) é uma complicação médica grave, frequente e prevenível em pacientes hospitalizados. Embora a eficácia de sua prevenção tenha sido demonstrada, a adesão à tromboprofilaxia continua insuficiente em nível internacional e nacional.  Objetivos: analisar o risco de TEV e o cumprimento da indicação de tromboprofilaxia farmacológica em pacientes hospitalizados.  Metodologia: estudo observacional, descritivo e prospectivo envolvendo pacientes não críticos com condições médicas, cirúrgicas ou em período gravídico-puerperal em dois centros médicos terciários do Uruguai. Avaliou-se a porcentagem de pacientes em risco de TEV e, entre eles, a proporção que recebia tromboprofilaxia farmacológica. Após 3 meses, verificou-se a ocorrência de evento de TEV.  Resultados: foram incluídos 229 pacientes. Do total, 68,1% apresentavam risco de TEV segundo o escore PADUA, dos quais 53,2% recebiam profilaxia farmacológica. Quando aplicado o escore UTAH, 72,5% estavam em risco de TEV, dos quais 53% recebiam profilaxia farmacológica. Nenhum dos pacientes com contraindicação à tromboprofilaxia farmacológica recebeu medidas mecânicas. 26,2% dos pacientes com patologia cirúrgica em risco de TEV recebiam tromboprofilaxia farmacológica. Dez pacientes com patologia clínica estavam em risco segundo o escore UTAH, mas não segundo o PADUA. O seguimento em 3 meses foi alcançado em 148 pacientes; 2 (1,4%) apresentaram um evento trombótico. Ambos tinham contraindicação à tromboprofilaxia farmacológica.  Conclusões: a adesão à prescrição de tromboprofilaxia ainda é insuficiente e é necessário continuar trabalhando.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tromboprofilaxis]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad tromboembólica venosa]]></kwd>
<kwd lng="es"><![CDATA[Adherencia]]></kwd>
<kwd lng="es"><![CDATA[Trombosis venosa profunda]]></kwd>
<kwd lng="es"><![CDATA[Embolia pulmonar]]></kwd>
<kwd lng="en"><![CDATA[Thromboprophylaxis]]></kwd>
<kwd lng="en"><![CDATA[Venous thromboembolism]]></kwd>
<kwd lng="en"><![CDATA[Adherence]]></kwd>
<kwd lng="en"><![CDATA[Deep vein thrombosis]]></kwd>
<kwd lng="en"><![CDATA[Pulmonary embolism]]></kwd>
<kwd lng="pt"><![CDATA[Tromboprofilaxia]]></kwd>
<kwd lng="pt"><![CDATA[Doença tromboembólica venosa]]></kwd>
<kwd lng="pt"><![CDATA[Adesão]]></kwd>
<kwd lng="pt"><![CDATA[Trombose venosa profunda]]></kwd>
<kwd lng="pt"><![CDATA[Embolia pulmonar]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geerts]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Bergqvist]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pineo]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Heit]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Samama]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Lassen]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2008</year>
<volume>133</volume>
<numero>6 Suppl 6</numero>
<issue>6 Suppl 6</issue>
<page-range>381S-453S</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindblad]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sternby]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Bergqvist]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of venous thromboembolism verified by necropsy over 30 years]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1991</year>
<volume>302</volume>
<numero>6778</numero>
<issue>6778</issue>
<page-range>709-11</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandler]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?]]></article-title>
<source><![CDATA[J R Soc Med]]></source>
<year>1989</year>
<volume>82</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>203-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alikhan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wilmott]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen a]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fatal pulmonary embolism in hospitalised patients: a necropsy review]]></article-title>
<source><![CDATA[J Clin Pathol]]></source>
<year>2004</year>
<volume>57</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1254-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kocher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Darbellay]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Damiana]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kopp]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Choffat]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tritschler]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overuse and underuse of thromboprophylaxis in medical inpatients]]></article-title>
<source><![CDATA[Res Pract Thromb Haemost]]></source>
<year>2023</year>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heit]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Silverstein]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Mohr]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Petterson]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Lohse]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Fallon]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The epidemiology of venous thromboembolism in the community]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>2001</year>
<volume>86</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>452-63</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neeman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Thai]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Clancy]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<source><![CDATA[Trends and Risk Factors for Venous Thromboembolism Among Hospitalized Medical Patients]]></source>
<year>2022</year>
<volume>5</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skeik]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Westergard]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Recommendations for VTE Prophylaxis in Medically Ill Patients]]></source>
<year>2020</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-44</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schunemann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cushman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Burnett]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Beyer-westendorf]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Spencer]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Society of Hematology 2018 guidelines for management of venous thromboembolism : prophylaxis for hospitalized and nonhospitalized medical patients]]></article-title>
<source><![CDATA[Blood Adv]]></source>
<year>2018</year>
<volume>2</volume>
<numero>22</numero>
<issue>22</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Dunn]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Cushman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dentali]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Akl]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of VTE in nonsurgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines]]></article-title>
<source><![CDATA[Chest [Internet]]]></source>
<year>2012</year>
<volume>141</volume>
<numero>2 SUPPL</numero>
<issue>2 SUPPL</issue>
<page-range>e195S-226S</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gould]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Wren]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Karanicolas]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Arcelus]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Heit]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of VTE in nonorthopedic surgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2012</year>
<volume>141</volume>
<numero>2 Suppl.</numero>
<issue>2 Suppl.</issue>
<page-range>227-77</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falck-Ytter]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Johanson]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Curley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[OE]]></given-names>
</name>
<name>
<surname><![CDATA[Schulman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of VTE in orthopedic surgery patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines]]></article-title>
<source><![CDATA[Chest [Internet]]]></source>
<year>2012</year>
<volume>141</volume>
<numero>2 Suppl.</numero>
<issue>2 Suppl.</issue>
<page-range>e278S-325S</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Crowther]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meade]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rabbat]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Griffith]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Schiff]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors]]></article-title>
<source><![CDATA[Crit Care Med [Internet]]]></source>
<year>2005</year>
<volume>33</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1565-71</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weitz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-molecular-weight heparins]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1997</year>
<volume>337</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>688</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samama]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[OE]]></given-names>
</name>
<name>
<surname><![CDATA[Quinlan]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mismetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rosencher]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quantification of risk factors for venous thromboembolism: A preliminary study for the development of a risk assessment tool]]></article-title>
<source><![CDATA[Haematologica]]></source>
<year>2003</year>
<volume>88</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1410-21</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Heit]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Prins]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lensing]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low molecular weight heparin: a critical analysis of clinical trials]]></article-title>
<source><![CDATA[Pharmacol Rev]]></source>
<year>1994</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>89</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wells]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Holloway]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Weitz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>1994</year>
<volume>71</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>300</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[BI]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[OE]]></given-names>
</name>
<name>
<surname><![CDATA[Rosencher]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kurth]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[van Dijk]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Frostick]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2007</year>
<volume>5</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2178-85</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<collab>The Re-mobilize Writing C</collab>
<article-title xml:lang=""><![CDATA[Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery]]></article-title>
<source><![CDATA[J Arthroplasty [Internet]]]></source>
<year>2009</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="">
<collab>NICE</collab>
<source><![CDATA[Venous thromboembolism in over 16s : reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Noventa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rossetto]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brandolin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Perlati]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua Prediction Score]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2010</year>
<volume>8</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2450-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caprini]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arcelus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[State-of-the-art venous thromboembolism prophylaxis]]></article-title>
<source><![CDATA[Scope Phlebol Lymphol [Internet]]]></source>
<year>2001</year>
<volume>8</volume>
<page-range>228-40</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bahl]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Henke]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Wakefield]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[D a]]></given-names>
</name>
<name>
<surname><![CDATA[Caprini]]></surname>
<given-names><![CDATA[J a]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A validation study of a retrospective venous thromboembolism risk scoring method]]></article-title>
<source><![CDATA[Ann Surg [Internet]]]></source>
<year>2010</year>
<volume>251</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>344-50</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woller]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Aston]]></surname>
<given-names><![CDATA[VT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients]]></article-title>
<source><![CDATA[Am J Med [Internet]]]></source>
<year>2011</year>
<volume>124</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>947-954.e2</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Estévez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trabajo multicéntrico sobre profilaxis de la Enfermedad Tromboembólica Venosa ( ETEV )]]></article-title>
<source><![CDATA[Arch Med Interna]]></source>
<year>2007</year>
<volume>29</volume>
<page-range>46-51</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carrizo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cuadro]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Merola]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pizzarossa]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adhesión insuficiente a la prevención de la enfermedad tromboembólica venosa en Hospitales Uruguayos. Un grave problema en salud]]></article-title>
<source><![CDATA[Rev Urug Med Interna]]></source>
<year>2020</year>
<volume>05</volume>
<numero>03</numero>
<issue>03</issue>
<page-range>4-13</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mérola]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pizzarossa]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Peverelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bruno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Venous Thromboembolism Risk and Adherence to Pharmacological Thromboprophylaxis in Hospitalized Patients in Uruguay: First Nationwide Study]]></article-title>
<source><![CDATA[Clin Appl Thromb]]></source>
<year>2024</year>
<volume>30</volume>
</nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caprini]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombosis risk assessment as a guide to quality patient care]]></article-title>
<source><![CDATA[Disease-a-Month]]></source>
<year>2005</year>
<volume>51</volume>
<numero>2&#8211;3</numero>
<issue>2&#8211;3</issue>
<page-range>70-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="book">
<collab>Royal College Obstetricians and Gynaecologists</collab>
<source><![CDATA[Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium Green-top Guideline No. 37a]]></source>
<year>2015</year>
<numero>37</numero>
<issue>37</issue>
<page-range>1-40</page-range><publisher-name><![CDATA[RCOG Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grille]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maggiari]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ojeda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherencia a las recomendaciones de tromboprofilaxis post-cesárea: estudio de corte transversal]]></article-title>
<source><![CDATA[Rev Med Chil]]></source>
<year>2021</year>
<volume>149</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>881-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schulman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kearon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Control]]></surname>
<given-names><![CDATA[ON]]></given-names>
</name>
<name>
<surname><![CDATA[Anticoagulation]]></surname>
<given-names><![CDATA[OF]]></given-names>
</name>
<name>
<surname><![CDATA[The]]></surname>
<given-names><![CDATA[OF]]></given-names>
</name>
<name>
<surname><![CDATA[Committee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients]]></article-title>
<source><![CDATA[J Thromb Haemost [Internet]]]></source>
<year>2005</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>692-4</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowswell]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Nokes]]></surname>
<given-names><![CDATA[TJC]]></given-names>
</name>
</person-group>
<source><![CDATA[Significant reduction in hospital-acquired thrombosis : impact of national risk assessment and real-time feedback]]></source>
<year>2017</year>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lester]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Freemantle]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Begaj]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pagano]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Fatal venous thromboembolism associated with hospital admission : a cohort study to assess the impact of a national risk assessment target]]></source>
<year>2013</year>
<page-range>1734-9</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spyropoulos]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Jr]]></surname>
<given-names><![CDATA[FAA]]></given-names>
</name>
</person-group>
<source><![CDATA[Identify Hospitalized Medical Patients at Risk for VTE]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bottaro]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ceresetto]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Emery]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bruetman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Emery]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pellegrini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cross-sectional study of adherence to venous thromboembolism prophylaxis guidelines in hospitalized patients]]></article-title>
<source><![CDATA[The Trombo-Brit study. Thromb J]]></source>
<year>2012</year>
<volume>10</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuzinatto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wajner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Waldemar]]></surname>
<given-names><![CDATA[FS de]]></given-names>
</name>
<name>
<surname><![CDATA[Hopf]]></surname>
<given-names><![CDATA[JL de S]]></given-names>
</name>
<name>
<surname><![CDATA[Schuh]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Barreto]]></surname>
<given-names><![CDATA[SSM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Venous thromboembolism prophylaxis in a general hospital]]></article-title>
<source><![CDATA[J Bras Pneumol publicacao Of da Soc Bras Pneumol e Tisilogia]]></source>
<year>2011</year>
<volume>37</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>160-7</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forgo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Micieli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ageno]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Castellucci]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Cesarman-Maus]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ddungu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2022</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>409-21</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Tapson]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
<name>
<surname><![CDATA[Bergmann]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Goldhaber]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Kakkar]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Deslandes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2008</year>
<volume>37</volume>
<page-range>387-94</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abboud]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Kahale]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dempster]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Adair]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Prevention of health care associated venous thromboembolism through implementing VTE prevention clinical practice guidelines in hospitalized medical patients : a systematic review and meta-analysis]]></source>
<year>2020</year>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raskob]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Venous thromboembolism : A Call for risk assessment in all hospitalised patients]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>2016</year>
<page-range>777-9</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blondon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Spirk]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kucher]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Aujesky]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hayoz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Beer]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<source><![CDATA[Comparative Performance of Clinical Risk Assessment Models for Hospital-Acquired Venous Thromboembolism in Medical Patients]]></source>
<year>2018</year>
<page-range>82-9</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chopard]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Spirk]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bounameaux]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identifying acutely ill medical patients requiring thromboprophylaxis]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2006</year>
<volume>4</volume>
<page-range>915-6</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pandor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tonkins]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Goodacre]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sworn]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Clowes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[XL]]></given-names>
</name>
</person-group>
<source><![CDATA[Risk assessment models for venous thromboembolism in hospitalised adult patients : a systematic review]]></source>
<year>2021</year>
<page-range>1-19</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blondon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andreas]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Marc]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Aujesky]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Méan]]></surname>
<given-names><![CDATA[MSM]]></given-names>
</name>
</person-group>
<source><![CDATA[Underuse of medical thromboprophylaxis in mobile elderly inpatients : The SWITCO65 + cohort]]></source>
<year>2021</year>
<page-range>142-7</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stuck]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Spirk]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schaudt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kucher]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Risk assessment models for venous thromboembolism in acutely ill medical patients A systematic review]]></source>
<year>2017</year>
<page-range>801-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
